UPTRAVI reduced hospitalizations for PAH1
This benefit was shown in a clinical trial that compared patients taking UPTRAVI® (selexipag) with those taking a placebo. Patients took UPTRAVI for an average of 1.4 years.
Patients taking UPTRAVI were able to walk farther than patients taking a placebo1
At 6 months, in a clinical trial, UPTRAVI helped patients walk an average of 12 meters (about 39 feet) more than patients taking placebo, as measured by the 6-minute walk distance (6MWD).